Related by context. All words. (Click for frequent words.) 67 imatinib therapy 66 riociguat 65 antitumor efficacy 65 lung fibrosis 65 immunological responses 64 hyperalgesia 64 antibody mediated 64 androgen deprivation 64 fulvestrant 64 opioid analgesia 64 virological response 64 EBV infection 63 CMV infections 63 immunosuppressive regimens 63 neutralizing antibody 63 intravenous cyclophosphamide 63 activin 63 B7 H3 63 interferon therapy 63 effector function 63 SERCA2a 62 TNF antagonist 62 IV bisphosphonates 62 K ras mutations 62 TGF beta signaling 62 Notch1 62 IDH mutations 62 virologic response 62 virologic responses 62 p# activation 62 CMV infection 62 remyelination 62 immunopathology 62 methotrexate therapy 62 PlGF 62 therapeutic regimens 62 cytopenias 62 HbF 62 erythropoiesis 62 immunosuppression 62 pharmacologic intervention 62 viral suppression 61 neurotrophic 61 transgene expression 61 alkaline phosphatase ALP 61 tipranavir 61 AGILECT R 61 trastuzumab Herceptin ® 61 virological suppression 61 antiviral potency 61 platelet activation 61 systemic toxicity 61 lung metastasis 61 engraftment 61 decitabine 61 Pseudomonas aeruginosa infections 61 hypoperfusion 61 coinfection 61 ADPKD 61 inotropic 61 pituitary hormone 61 CTAP# Capsules 61 Host Disease GvHD 61 thrombotic complications 61 antitumor effect 61 corticosteroid dexamethasone 61 lupus nephritis 60 flavopiridol 60 chronic GVHD 60 cortical excitability 60 dopaminergic therapy 60 EGFR expression 60 tumor necrosis 60 complete cytogenetic response 60 NAbs 60 DFMO 60 polyomavirus nephropathy 60 antibody responses 60 vidofludimus 60 myeloablative 60 Ribavirin causes 60 renal fibrosis 60 corticosteroid therapy 60 antifungal therapy 60 edifoligide 60 T2DM 60 platelet reactivity 60 Gleevec resistant 60 Symadex 60 IFN gamma 60 CMV reactivation 60 immune responses 60 pharmacokinetic interactions 60 EGFR tyrosine kinase inhibitors 60 nephrotoxicity 60 antitumor effects 60 microglial activation 60 antiangiogenic therapy 60 paricalcitol 60 IFN beta 60 axonal regeneration 60 immunomodulation 60 GvHD 60 mediated immunity 60 immunomodulatory therapy 60 chemosensitivity 60 HAART regimens 60 Th2 responses 60 seropositive patients 60 pDCs 60 durable remissions 60 chemoresistance 60 antithrombotic therapy 59 Kinoid 59 IFN γ 59 elacytarabine 59 posaconazole 59 posttransplant 59 allograft rejection 59 CMV disease 59 SSc 59 delayed CINV 59 STAT3 signaling 59 coadministration 59 immunosuppressive agents 59 TroVax ® 59 parkinsonian symptoms 59 neurologic progression 59 effector functions 59 platelet inhibition 59 pressor response 59 tumorigenicity 59 cilengitide 59 locoregional disease 59 TNFa 59 antimicrobial prophylaxis 59 vasodilatation 59 autoregulation 59 mycophenolate mofetil 59 allogeneic HSCT 59 GRNCM1 59 PDGFR 59 anti leukemic 59 virologic 59 aromatase inhibitor therapy 59 Akt1 59 complete remissions 59 CLORETAZINE TM VNP#M 59 rhTSH 59 Chronic pancreatitis 59 relapsed AML 59 acute GvHD 59 XmAb# 59 ischaemia 59 heavily pretreated 59 gut mucosa 59 mTOR inhibitors 59 tumor regression 59 viremia 59 metastatic lung cancer 59 TNF α 59 PROCHYMAL 59 cytoreduction 59 hepatic toxicity 59 resynchronization therapy 59 ImmuKnow 59 antitumor responses 59 hepatic fibrosis 59 relapsed ovarian cancer 59 Dasatinib 59 aminotransferases 59 ventricular remodeling 59 liver histology 59 HBeAg 59 PTH secretion 59 acute decompensation 59 adrenalectomy 59 mucociliary clearance 59 invasive candidiasis 59 PTLD 59 myocardial reperfusion 59 bleomycin 59 intravesical therapy 59 Candida infection 59 immunologically 59 fluvastatin 59 standard chemotherapy regimens 59 noninfectious uveitis 59 allergic inflammation 59 HBeAg negative 59 activate p# 59 cerebral ischemia 59 CD8 responses 59 immunosuppressive medication 59 viral reactivation 59 Hydroxyurea 59 stratifying patients 59 antibody titers 59 Th1 cells 59 neuro degeneration 59 HIV HCV coinfected 59 serum calcium 59 anti angiogenic therapies 59 ectopic expression 59 neurite outgrowth 59 EGFR inhibitors 59 metastatic RCC 59 nonsense mutation 59 Epratuzumab 59 neutralizing antibodies 59 antibody titer 59 IgG4 59 autophagic 59 H. pylori eradication 59 serum phosphate 59 neutrophil counts 59 induce remission 59 intravascular hemolysis 59 T1DM 59 Fc receptor 59 glucose homeostasis 59 mGluR5 antagonist 59 antitumor activity 59 Telintra 59 esophageal candidiasis 59 perioperative morbidity 59 rBChE 59 otelixizumab 59 hyperphenylalaninemia HPA due 59 Bcl xL 59 carcinoid 59 adrenal suppression 59 ADAMTS# 59 antioxidant supplementation 59 FOXP3 59 EGFR TKI 58 PTHrP 58 rFVIIa 58 cardioprotection 58 serum calcium levels 58 IRX 2 58 nucleotide analog 58 menadione 58 SIV infection 58 prostate carcinogenesis 58 radiographic progression 58 granulocyte 58 immune suppression 58 indolent NHL 58 CYP#D# genotype 58 humoral 58 neointimal hyperplasia 58 molecular remissions 58 antiarrhythmic drugs 58 dexpramipexole 58 antiviral efficacy 58 metastatic lesions 58 pyridostigmine 58 MGd 58 Natalizumab 58 serum HBV DNA 58 biochemical abnormalities 58 HIF PHI 58 plasma pharmacokinetics 58 immunocompetent 58 kidney allograft 58 hedgehog pathway 58 suppress viral replication 58 lenalidomide dexamethasone 58 viraemia 58 epithelial barrier 58 cytotoxic therapy 58 basiliximab 58 plasma kallikrein 58 OHR/AVR# 58 synthase TS 58 DACH platinum 58 allogeneic bone marrow 58 deferiprone 58 angiogenesis inhibition 58 FVIII 58 CLA supplementation 58 PASI scores 58 viral kinetics 58 N Myc 58 NADPH oxidase 58 motor neuron degeneration 58 BRAF inhibitors 58 fibrinolysis 58 renal toxicity 58 GIST tumors 58 vivo potency 58 androgen suppression therapy 58 DAPT 58 ADAGIO study 58 axon regeneration 58 uric acid lowering 58 ciclosporin 58 Tavocept 58 INVEGA ® 58 M#V mutation 58 serum urate levels 58 GRK2 58 humoral immune response 58 malignant transformation 58 endotoxemia 58 colorectal cancer liver metastases 58 TNFα 58 mitochondrial dysfunction 58 H. pylori infection 58 reperfusion injury 58 TNF inhibitor 58 leukemia ALL 58 glycated hemoglobin levels 58 DNA demethylation 58 neuroregenerative 58 IFN alpha 58 intestinal microflora 58 Immune responses 58 glucocorticoid 58 chlamydial infection 58 sustained virological response 58 glutamate signaling 58 CGEN # 58 hyperoxia 58 beta blocker therapy 58 locoregional 58 transplanted islets 58 calcitriol 58 lactate dehydrogenase 58 HSCT 58 hematopoietic cells 58 uPA 58 dexrazoxane 58 antitumor immunity 58 TRAIL induced apoptosis 58 CD8 T cells 58 SNT MC# 58 lethal arrhythmias 58 dose cyclophosphamide 58 demyelinating 58 steroid dexamethasone 58 pathogenic mechanisms 58 hematologic toxicity 58 lymphoid organs 58 beta globin gene 58 diabetic kidney 58 virologic suppression 58 samalizumab 58 enzastaurin 58 hemodilution 58 neurocognitive deficits 58 levodopa therapy 58 EGFr 58 canakinumab 58 cAMP signaling 58 ischemic cardiomyopathy 58 Treg cell 58 small molecule activators 58 renal tubular 58 immunosuppressant drug 58 IL 1ß 58 cytotoxic effects 58 interleukin IL -# 58 growth hormone secretion 58 retransplantation 58 antidepressant efficacy 58 suppressor cells 58 DHEA supplementation 58 coinfected patients 58 chitinase 58 innate immune responses 58 TNFalpha 58 S/GSK# 58 LVNC 58 hemodynamic instability 58 gonadotropins 58 LTBI 58 CLL cells 58 motoneurons 57 Imatinib 57 fibrin deposition 57 pCR 57 Interferon alpha 57 progranulin 57 cathepsin K 57 HER2 overexpression 57 immunological 57 type 1diabetes 57 MMP inhibitors 57 thyrotropin 57 NF kB pathway 57 N. gonorrhoeae 57 busulfan 57 leukocyte recruitment 57 HIF PH inhibitors 57 bendamustine 57 HBeAg seroconversion 57 NPM1 mutation 57 cardiac biomarkers 57 NAGS deficiency 57 Akt activation 57 hepatitis B infection 57 lymphocytosis 57 seroprotection 57 adrenal function 57 imatinib Gleevec 57 Vidofludimus 57 CD8 T cell 57 AST ALT 57 ispinesib administered 57 autologous transplants 57 humoral responses 57 urate levels 57 milatuzumab 57 antiandrogens 57 radioiodine therapy 57 decompensated cirrhosis 57 Smad3 57 CaM kinase II 57 chlamydial 57 fenretinide 57 systemic immunosuppressive 57 androgen therapy 57 curative resection 57 gastric carcinoma 57 thrombopoietin 57 carbohydrate absorption 57 tyrosine phosphorylation 57 aldosterone antagonists 57 mTOR inhibition 57 C1q 57 immunosuppressive therapies 57 clinically localized prostate 57 HBV infections 57 leukemic stem cells 57 BRAF mutation 57 clotting cascade 57 Ataluren 57 idraparinux 57 combination antiretroviral therapy 57 androgen ablation 57 prognostic indicator 57 anemia hemoglobin 57 nerve degeneration 57 Tumor shrinkage 57 PNH patients 57 MYCN amplification 57 MS relapses 57 bacterial colonization 57 CIMZIA ™ 57 beta lactam antibiotic 57 androgen receptor AR 57 colorectal carcinoma 57 EGFR mutations 57 relapsed SCLC 57 IKK2 57 hemorrhagic complications 57 Azedra 57 allogeneic transplantation 57 neuronal function 57 APTIVUS 57 pharmacodynamic profile 57 alfa interferon 57 p# biomarker 57 alpha interferon 57 cinacalcet 57 MP4OX 57 ventricular dysfunction 57 TTR gene 57 MAPK pathway 57 pomalidomide 57 Fluid retention 57 basal cell nevus syndrome 57 favorable pharmacokinetic profile 57 eosinophil count 57 inecalcitol 57 acute hepatic 57 leukocytosis 57 neoplastic cells 57 apremilast 57 methicillin susceptible Staphylococcus aureus 57 overlapping toxicities 57 benfotiamine 57 cisplatin chemotherapy 57 prostate cancer CRPC 57 mapatumumab 57 tumoral 57 serum concentrations 57 immune dysregulation 57 MIF gene 57 Clusterin 57 invasive aspergillosis 57 vWF 57 haematopoietic 57 Bezielle 57 YONDELIS 57 axonal damage 57 idarubicin 57 myelosuppression 57 WNV encephalitis 57 surgical debulking 57 tumor regressions 57 fibrotic disease 57 interferon IFN 57 clinically meaningful reductions 57 Leydig cell 57 recurrent glioblastoma multiforme 57 HuMax CD# 57 neutropenic patients 57 GRNOPC1 cells 57 metastatic neuroendocrine tumors 57 Th2 cytokines 57 extrapyramidal symptoms EPS 57 pertuzumab 57 TNF alpha antagonist 57 cabazitaxel 57 vasogenic edema 57 immunodeficient 57 tau phosphorylation 57 neurotrophic factor 57 azacitidine 57 NF kappaB activation 57 eflornithine 57 dose proportional pharmacokinetics 57 hour bronchodilation 57 cerebral vasospasm 57 ruxolitinib 57 MyVax R 57 sJIA 57 HAART regimen 57 Tamibarotene 57 MYDICAR ® 57 interferon alpha 57 demyelination 57 transplantation HCT 57 PXD# 57 PKCi 57 HER2 expression 57 adefovir 57 dosage regimens 57 radiochemotherapy 57 Degarelix 57 costimulation 57 CD4 lymphocyte count 57 NNRTIs 57 leukemia AML 57 EDEMA3 trial 57 NNRTI resistant virus 57 immune modulator 57 recombinant erythropoietin 57 acute GVHD 57 intracranial hemorrhage ICH 57 teriflunomide 57 TLR signaling 57 genotypic resistance 57 protease inhibitor PI 57 cranial irradiation 57 forskolin 57 anticancer activity 57 epithelial tumors 57 thrombocytosis 57 Non inferiority 57 tumor recurrence 57 hemoglobin Hb 57 EndoTAG TM -1 57 dose ritonavir 57 pharmacological interventions 57 intra arterial chemotherapy 57 stem cell engraftment 57 Sym# 57 CD4 + T 57 clonogenic 57 dyskeratosis congenita 57 ACZ# 57 dystrophin expression 57 ribavirin therapy 57 hepatorenal syndrome 57 pulmonary exacerbations 57 experimental autoimmune encephalomyelitis 57 angiogenesis inhibitor 57 poststroke depression 57 airway hyperresponsiveness 57 T#I [002] 57 mixed hyperlipidemia 57 efalizumab 57 velafermin 57 FVIIa 57 neuropsychological impairments 57 beta adrenergic receptor 57 chromosomal rearrangement 57 chronic granulomatous disease 57 cell transplantation 57 steroid refractory 57 HuLuc# 57 testosterone supplementation 57 GLYX 57 vitamin B# folic acid 57 endocrine therapies 57 ProSavin 57 VEGF inhibition 57 HPA axis 57 choroidal neovascularization 57 Hematologic toxicity 57 superinfection 57 proliferative diabetic retinopathy 57 serum phosphate levels 57 cardiac dysfunction 57 bactericidal activity 57 inhibitory effects 57 BH4 57 FXIII 57 dexanabinol 57 bFGF 57 FasL 57 SCIg 57 response CCyR 57 hypoxemia 57 LymphoStat B belimumab 57 ximelagatran 57 amyloid deposition 57 potentiation 57 potent antiretroviral therapy 57 cells MSCs 57 leukaemic stem cells 57 Gag polymorphisms 57 neovascular 57 hematological toxicity 57 PDE7B 57 CD8 + 57 anti angiogenic agents 57 Helicobacter infection 57 gastrointestinal stromal tumors GIST 57 CYP #A# 57 alteplase 57 costimulatory molecules 56 chloride secretion 56 APOPTONE 56 oncogenesis 56 tumor regrowth 56 inflammatory cytokine 56 ovarian carcinoma 56 alanine aminotransferase ALT 56 omega interferon 56 ZOLINZA 56 Lixivaptan 56 cardiac repolarization 56 trabectedin 56 disease progression 56 anticancer therapy 56 TRAIL R2 56 anti angiogenic drugs 56 ELACYT 56 Fludarabine 56 cytoprotective 56 DHFR 56 hematologic disorders 56 lymph node dissection 56 KRAS status 56 telomerase activity 56 spermatogenesis 56 platelet inhibitor 56 natriuretic peptide 56 CD4 + T lymphocytes 56 recurrent glioblastoma 56 imipenem 56 acute humoral rejection 56 Traficet EN 56 haematological 56 melanoma tumors 56 MCyR 56 GVHD 56 insulin secreting cells 56 cis RA 56 Certolizumab pegol 56 TRV# [001] 56 SRBD 56 NATRECOR ® 56 nonischemic 56 anti HBs 56 E. faecalis 56 circulating lymphocytes 56 HNSCC 56 iniparib 56 antiviral activity 56 serum PTH 56 SOCS1 56 CFTR gene 56 Diamyd r vaccine 56 glucocorticoid receptors 56 rEV# 56 CBLC# 56 TGF ß 56 glioma cells 56 hyperglycaemia 56 hyperprolactinemia 56 mutated KRAS 56 PRT# 56 probiotic supplementation 56 p# Shc 56 L dopa 56 β cell 56 pyrazinamide 56 C1 INH 56 hA# 56 ganciclovir 56 variceal hemorrhage 56 imatinib resistance 56 rapid virological response 56 severe neutropenia 56 PR interval prolongation 56 autonomic dysfunction 56 VAPRISOL 56 renal allograft 56 HCV replicon 56 lowering blood glucose 56 biofilm formation 56 trabedersen 56 JAK inhibitors 56 androgen receptor signaling 56 antiangiogenic agents 56 hormone refractory 56 atypical hemolytic uremic syndrome 56 vascular dysfunction 56 cardioprotective effects 56 SMN protein 56 hedgehog signaling 56 hippocampal atrophy 56 neurofibromin 56 NGAL 56 CIMZIA TM 56 TKI therapy 56 intracellular bacteria 56 immunoreactivity 56 nNOS 56 bezafibrate 56 Vpu 56 PSA nadir 56 CD4 + 56 cytokine signaling 56 PegIFN RBV 56 neuronal dysfunction 56 intensive statin therapy 56 IL 1β 56 anagrelide 56 HBeAg positive 56 R0 resection 56 EGF receptor 56 antithymocyte globulin 56 intravenous diuretics 56 granzyme B 56 pancreatic adenocarcinoma 56 p#HER# 56 N acetylcysteine 56 CEACAM1 56 vaso occlusive crisis 56 morphometric vertebral fractures 56 indolent lymphomas 56 immunodeficiency disorders 56 amphotericin B 56 enzymatic activity 56 alkylating agent 56 Doxil ® 56 collagen degradation 56 LHRH agonists 56 favorable tolerability 56 eculizumab therapy 56 CFTR protein 56 tumor xenograft models 56 PKM2 56 GPIIb IIIa 56 mucosal healing 56 autoimmune reactions 56 tuberculin skin testing 56 prostate epithelial cells 56 CTLs 56 lung epithelium 56 oncomodulin 56 PITX2 methylation 56 candidemia 56 BRAF inhibitor 56 erythropoietic 56 JAK3 56 BRAF V# mutation 56 contractile function 56 proto oncogene 56 hypovolemic 56 membranous nephropathy 56 p# MAPK 56 lymphocyte activation 56 liver metastases 56 low dose ritonavir 56 viral replication 56 baminercept 56 rhIL 7 56 sunitinib 56 inhaled nitric oxide 56 hypotensive 56 G CSF 56 transfusion transmitted 56 autologous transplantation 56 rt PA 56 artery stenosis 56 cranial radiation 56 NLX P# 56 chromosomal mutations 56 pegylated liposomal doxorubicin 56 beta interferon 56 aldosterone antagonist 56 allogeneic transplant 56 JAK STAT pathway 56 HCV infected 56 CFTR inhibitors 56 cTnI 56 atherogenic dyslipidemia 56 immunosuppressed patients 56 immunosuppressive regimen 56 antiangiogenesis 56 Pagoclone 56 follicular lymphomas 56 hypercalcemia 56 isoenzyme 56 IGFBP2 56 GeoVax vaccine 56 β catenin 56 percutaneous cryoablation 56 lymphocyte counts 56 Hypotension 56 antiangiogenic 56 CD# upregulation 56 non pharmacological interventions 56 prostate cancer CaP 56 rifamycins 56 telomere shortening 56 striatal neurons 56 Thiovir 56 TGF β 56 downregulating 56 pharmacokinetic characteristics 56 VIR# 56 Stat5 56 liver transplant recipients 56 humoral immunity 56 glomerular filtration 56 RLY# 56 CDK inhibitor 56 sotalol 56 neovascularization 56 angiographic outcomes 56 Garcia Manero 56 mg kg dose 56 NPM1 56 neuroinflammatory 56 HIV RNA 56 ATTR CM 56 QT interval prolongation 56 recurrent VTE 56 fluoroquinolone resistance 56 ATIR 56 MALT lymphoma 56 oral FTY# 56 NKG2D 56 thyroglobulin 56 relapsed MM 56 N cadherin 56 osteoclast activity 56 PKC beta 56 HER2 receptors 56 hepatocellular carcinomas 56 parasitemia 56 CGRP 56 heavily pretreated patients 56 Adjuvant therapy 56 ACh 56 preclinically 56 nucleoside analogues 56 APTIVUS r 56 glycemia 56 Gleevec imatinib 56 dopaminergic cells 56 tumor vasculature 56 antiretroviral naive 56 E cadherin expression 56 CP CPPS 56 Pegylated Interferon 56 preserved ejection fraction 56 S. maltophilia 56 elevated serum creatinine 56 ApoA1 56 prognostically 56 CCX# 56 smoldering multiple myeloma 56 transthyretin 56 symptomatic VTE 56 NKT cell 56 neurologic deficits 56 PAOD 56 calcineurin inhibitors 56 immunosuppressant therapy 56 immune modulating 56 E#F# 56 nonalcoholic steatohepatitis NASH 56 multidrug resistance 56 prognostic marker 56 blood phenylalanine Phe 56 viral titers 56 amikacin 56 sustained virologic response 56 thrombotic thrombocytopenic purpura TTP 56 LHRH antagonists 56 node metastases 56 invasive fungal infections 56 gastric mucosa 56 nitazoxanide 56 underlying pathophysiology 56 HeFH 56 pelvic lymphadenectomy 56 EGFR mutation status 56 lipid lowering therapies 56 Severe Primary IGFD 56 OAB symptoms 56 haematological toxicity 56 QTc prolongation 56 rindopepimut 56 clusterin 56 receptor inhibitor 56 Nilotinib 56 ERK1 2 56 virologically 56 VEGF receptor inhibitor 56 elotuzumab 56 alfentanil 56 ponatinib 56 DMARDS 56 somatostatin analogues 56 Treg cells 56 PARP inhibition 56 bone marrow suppression 56 fumagillin nanoparticles 56 rechallenge 56 downregulation 56 activated lymphocytes 55 ENMD # 55 hereditary deficiency 55 motesanib 55 hippocampal neurons 55 cediranib 55 variceal bleeding 55 taxane refractory 55 ATL# [001] 55 Anthracycline 55 CD4 + cells 55 plasma uric acid 55 Zevalin consolidation 55 dasatinib Sprycel 55 treprostinil 55 ESBA# 55 erlotinib Tarceva 55 relapsing remitting MS RRMS 55 RoACTEMRA 55 mitochondrial function 55 tocilizumab 55 effector T 55 parathyroid hormone PTH 55 biomarker assay 55 cardiac fibrosis 55 salivary function 55 transgenic rats 55 arterial calcification 55 lymph node metastasis 55 euthymic patients 55 renal kidney 55 decompensated heart failure 55 platelet counts 55 interferon gamma 55 transplanted bone marrow 55 miglustat 55 C. neoformans 55 Thrombocytopenia 55 peginterferon 55 Revimmune 55 replicon 55 temsirolimus 55 ischemia reperfusion injury 55 LRAT 55 TYSABRI natalizumab 55 dystrophin 55 Elocalcitol 55 ventricular arrhythmias 55 docetaxel Taxotere ® 55 β blockers 55 Prognostic factors 55 Vacc 4x 55 renal flares 55 SLC#A# [002] 55 EpCAM expression 55 biologic plausibility 55 cervical lymph nodes 55 corticosterone levels